PG
Philippe Gabant
Technoport
Head of Heathtech and life science
Description
Philippe holds a PhD in Molecular Biology from the Université Libre de Bruxelles (ULB) obtained in 1993 and a Master in Management de l’Innovation from HEC Saint Louis (Brussels, Belgium) obtained in 1995.
In 1995-1996 Philippe did a post-doctoral research at the University of Edinburgh (UK). During this research he discovered using mouse model the function of the alpha-fetoprotein the major embryonic plasma protein in mammalian development.
During his academic research career he was involved has an inventor in the development of a portfolio of genetic selection patented technologies.
One of these technologies belonging to ULB was licensed to Life technologies and is on the market since 1995 it is today a standard in DNA assembly method: Gateway technology, TOPO cloning. Other technologies were licensed to Sanofi-Pasteur, GSK and Merck to improve biopharmaceutical production. Since 2001-to 2012 Philippe was the Founder and CEO of Delphi Genetics today part of CATALENT.
From 2013 to 2025 Philippe was the founder and Chief Scientific Officer of Syngulon a startup focusing on genetic innovations to improve the biocontrol of microbial population using bacteriocins (antimicrobial peptides). Philippe has established several partnerships for the company with academics and industries.
From September 2025 to January 2026 Philippe was hired by the University of Luxembourg (UNI) to manage the Bioincubator.
From February 2026 Philippe is heading the Healthtech and life science sector for technoport the Luxembourg deeptech incubator.
Loading